bristol myers squibb news

MarketWatch · 1d

Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day

The stock's fall snapped a two-day winning streak.

Insider Monkey on MSN · 2d

Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?

We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks.

bovnews · 1d

Bristol-Myers Squibb Co (BMY) Stock: Greater Than Its Current Valuation?

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock to Neutral,

MarketWatch · 2d

Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains

This was the stock's second consecutive day of gains.

Insider Monkey on MSN · 9d

Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024?

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other pharma dividend stocks.

Benzinga.com · 9d

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale activity within a strike price range from $43.0 to $75.0 in the last 30 days.

bovnews · 3d

Why Did Bristol-Myers Squibb Co (BMY) Stock See 4.37% Surge in the Last 90 Days?

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low of $56.

Business Insider · 1d

Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research

MarketWatch · 3d

Bristol Myers Squibb Co. stock rises Monday, still underperforms market

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

10d

Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Yahoo Finance2d

Bristol-Myers Squibb Company (BMY)

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks. As retirement approaches, ensuring financial stability becomes ...

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.